KURA Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
22.8M
+9.4%
20.9M
+14.3%
18.3M
+5.4%
17.3M
-16.5%
20.8M
Cost of Revenue
371.0K
+52.7%
243.0K
-7.3%
262.0K
+359.6%
57.0K
0
Gross Profit
22.5M
+8.9%
20.6M
+14.6%
18.0M
+4.2%
17.3M
-16.7%
20.8M
Operating Expenses
66.5M
-28.9%
93.6M
-3.3%
96.8M
-6.5%
103.5M
+2.8%
100.7M
R&D
66.9M
+8.1%
61.9M
-5.2%
65.3M
+1.3%
64.4M
-5.2%
67.9M
SG&A
30.2M
-4.7%
31.8M
+0.6%
31.6M
-19.4%
39.1M
+19.2%
32.8M
Operating Income
-44072000
+39.6%
-73010000
+7.4%
-78815000
+8.6%
-86268000
-7.8%
-79997000
EBITDA
-43743000
+39.8%
-72641000
+7.4%
-78460000
+8.6%
-85865000
-7.6%
-79833000
Net Income
-70215000
-2.8%
-68327000
+6.8%
-73333000
+9.5%
-80999000
-9.3%
-74116000
EPS (Basic)
$-0.78
-1.3%
$-0.77
+7.2%
$-0.83
+9.8%
$-0.92
-8.2%
$-0.85
EPS (Diluted)
$-0.78
-1.3%
$-0.77
+7.2%
$-0.83
+9.8%
$-0.92
-8.2%
$-0.85
Shares (Diluted)
89.8M
+1.1%
88.9M
+0.3%
88.6M
+0.6%
88.1M
+0.5%
87.6M
Kura Oncology (KURA) — Financials